Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03613844 · ClinicalTrials.gov registry record · Phase 2
DHA Brain Delivery Trial
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
NCT03613844 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 365 participants.
The verdict
NCT03613844, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
Study Summary
Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is associated with reduced delivery of DHA to the brain. This information will help us identify the target population that could benefit from DHA supplementation to prevent cognitive decline.
Interventions
- DRUG Placebo
- DRUG DHA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2024-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03613844
The ClinicalTrials.gov registry entry for NCT03613844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03613844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03613844 about?
NCT03613844 is a clinical study titled "DHA Brain Delivery Trial". Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is associated with reduced delivery of DHA to the brain. This information will help us identify the target population that ...
What is the current status of trial NCT03613844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2018-09-01. Estimated completion is 2024-05-16.
What interventions are being tested in trial NCT03613844?
The interventions under investigation include: Placebo (DRUG), DHA (DRUG).
Who is sponsoring clinical trial NCT03613844?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.